Will Novartis Help You Retire Rich?

Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap. In this series, I look at 10 measures to show what makes a great retirement-oriented stock.

Many drug companies lately have had their shareholders nervous about looming patent cliffs. When blockbuster drugs go off-patent, they can present big challenges to the companies that have benefited from patent protection for years. Novartis (NYSE: NVS  ) , however, plays both sides of the fence, with both proprietary drugs and generics of its own. Can Novartis buck the headwinds that fellow European stocks have faced? Below, we'll revisit how Novartis does on our 10-point scale.

The right stocks for retirees
With decades to go before you need to tap your investments, you can take greater risks, weighing the chance of big losses against the potential for mind-blowing returns. But as retirement approaches, you no longer have the luxury of waiting out a downturn.

Sure, you still want good returns, but you also need to manage your risk and protect yourself against bear markets, which can maul your finances at the worst possible time. The right stocks combine both of these elements in a single investment.

When scrutinizing a stock, retirees should look for:

  • Size. Most retirees would rather not take a flyer on unproven businesses. Bigger companies may lack their smaller counterparts' growth potential, but they do offer greater security.
  • Consistency. While many investors look for fast-growing companies, conservative investors want to see steady, consistent gains in revenue, free cash flow, and other key metrics. Slow growth won't make headlines, but it will help prevent the kind of ugly surprises that suddenly torpedo a stock's share price.
  • Stock stability. Conservative retirement investors prefer investments that move less dramatically than typical stocks, and they particularly want to avoid big losses. These investments will give up some gains during bull markets, but they won't fall as far or as fast during bear markets. Beta measures volatility, but we also want a track record of solid performance as well.
  • Valuation. No one can afford to pay too much for a stock, even if its prospects are good. Using normalized earnings multiples helps smooth out one-time effects, giving you a longer-term context.
  • Dividends. Most of all, retirees look for stocks that can provide income through dividends. Retirees want healthy payouts now and consistent dividend growth over time -- as long as it doesn't jeopardize the company's financial health.

With those factors in mind, let's take a closer look at Novartis.

Factor

What We Want to See

Actual

Pass or Fail?

Size Market cap > $10 billion $133 billion Pass
Consistency Revenue growth > 0% in at least four of five past years 5 years Pass
  Free cash flow growth > 0% in at least four of past five years 3 years Fail
Stock stability Beta < 0.9 0.17 Pass
  Worst loss in past five years no greater than 20% (6.9%) Pass
Valuation Normalized P/E < 18 16.13 Pass
Dividends Current yield > 2% 4.6% Pass
  5-year dividend growth > 10% 13.6% Pass
  Streak of dividend increases >= 10 years 7 years Fail
  Payout ratio < 75% 58.9% Pass
       
  Total score   8 out of 10

Source: S&P Capital IQ. Total score = number of passes.

Since we looked at Novartis last year, the company has dropped a point. Yet the small fall in free cash flow that cost it that point shouldn't pose a big threat to the drugmaker.

Novartis is unusual in its two-pronged approach toward drug production. On one hand, it has a stable of branded drugs. Yet it also produces generics through its Sandoz division, a model that puts it into direct competition with primary generic-maker Teva Pharmaceutical (Nasdaq: TEVA  ) .

Generics have brought Novartis some big successes, especially as it marketed generic versions of blockbuster drugs including Sanofi's (NYSE: SNY  ) Lovenox and Lilly's (NYSE: LLY  ) Gemzar. Moreover, as those companies and several others face patent cliffs on other drugs, Novartis will see even more opportunity from generics.

But Novartis has had some troubles lately. Its Gilenya treatment for MS has raised cocnerns about unexplained deaths, boosting prospects for potential competitor Biogen Idec (Nasdaq: BIIB  ) and its BG-12 pipeline drug. Moreover, the company had to close a Nebraska plant temporarily earlier this year and issue a recall of over-the-counter products including Excedrin and Bufferin. With hypertension drug Diovan going off patent, Novartis will need help keeping its sales up.

For retirees and other conservative investors, Novartis has an extremely healthy dividend. The question, though, is whether the company is poised to survive patent expirations. With its generic division, Novartis actually has more going for it than many of its competitors.

Keep searching
Finding exactly the right stock to retire with is a tough task, but it's not impossible. Searching for the best candidates will help improve your investing skills, and teach you how to separate the right stocks from the risky ones.

If you really want to retire rich, no one stock will get the job done. Instead, you need to know how to prepare for your golden years. The Motley Fool's latest special report will give you all the details you need to get a smart investing plan going, plus it reveals three smart stocks for a rich retirement. But don't waste another minute -- click here and read it today.

Add Novartis to My Watchlist, which will aggregate our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned in this article. The Motley Fool owns shares of Teva Pharmaceutical. Motley Fool newsletter services have recommended buying shares of Teva Pharmaceutical and Novartis. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 03, 2012, at 6:25 AM, TheNats wrote:

    Mr. Caplinger - Nice article - But I don't agree that NVS failed the consecutive dividend test - I believe that it has increased dividends - including the latest - for over 10 years. I really curious - and maybe wrong - could you tell us where the 7 years came from?

  • Report this Comment On March 07, 2012, at 9:32 AM, TMFGalagan wrote:

    @TheNats -

    Dividend data came from Yahoo Finance, which states that the company didn't make a 2005 dividend payment. But Novartis investor relations says the dividend has actually increased in Swiss franc terms for 15 years: http://www.novartis.com/investors/share-data-analysis/divide...

    I'll ask for a score adjustment. Thanks for commenting!

    best,

    dan (TMF Galagan)

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1796247, ~/Articles/ArticleHandler.aspx, 12/20/2014 8:50:23 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement